Compounds > n-(2-(methylamino)ethyl)-5-isoquinolinesulfonamide
Page last updated: 2024-10-28

n-(2-(methylamino)ethyl)-5-isoquinolinesulfonamide and Osteogenic Sarcoma

n-(2-(methylamino)ethyl)-5-isoquinolinesulfonamide has been researched along with Osteogenic Sarcoma in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Adachi, S1
Kubota, M1
Lin, YW1
Okuda, A1
Matsubara, K1
Wakazono, Y1
Hirota, H1
Kuwakado, K1
Akiyama, Y1

Trials

1 trial available for n-(2-(methylamino)ethyl)-5-isoquinolinesulfonamide and Osteogenic Sarcoma

ArticleYear
In vivo administration of granulocyte colony-stimulating factor promotes neutrophil survival in vitro.
    European journal of haematology, 1994, Volume: 53, Issue:3

    Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adolescent; Burkitt Lymphoma; Cell Survival; Child; C

1994